Chemotherapeutic implications in microsatellite unstable colorectal cancer

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Cancer Biomarkers

• Publication date

  2006-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3233/CBM-2006-21-206PMID 17192059PMCID PMC4948976
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Influence of target gene mutations on survival, stage and histology in sporadic microsatellite unstable colon cancers

  2006cited by this paper
• A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer

  2005cited by this paper
• A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.

  2005cited by this paper
• DNA Mismatch Repair-dependent Response to Fluoropyrimidine-generated Damage*

  2005cited by this paper
• Systematic review of microsatellite instability and colorectal cancer prognosis.

  2005influential reference
• DNA mismatch repair deficiency, resistance to cancer chemotherapy and the development of hypersensitive agents.

  2005cited by this paper
• Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer

  2005influential reference
• The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer

  2005cited by this paper
• Cancer Statistics, 2005

  2005cited by this paper
• Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging.

  2005cited by this paper
• Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase.

  2004cited by this paper
• Apoptotic signaling in response to a single type of DNA lesion, O(6)-methylguanine.

  2004cited by this paper
• Hypersensitivity of Tumor Cell Lines with Microsatellite Instability to DNA Double Strand Break Producing Chemotherapeutic Agent Bleomycin

  2004cited by this paper
• Survival after adjuvant 5‐FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer

  2004cited by this paper
• The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: implications for chemosensitivity and resistance.

  2004cited by this paper
• Loss of activin receptor type 2 protein expression in microsatellite unstable colon cancers.

  2004cited by this paper
• Dependence of the Cytotoxicity of DNA-Damaging Agents on the Mismatch Repair Status of Human Cells

  2004cited by this paper
• Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer.

  2004influential reference
• Killing and mutagenic actions of dacarbazine, a chemotherapeutic alkylating agent, on human and mouse cells: effects of Mgmt and Mlh1 mutations.

  2004cited by this paper
• Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer.

  2003cited by this paper
• Role of hMLH1 promoter hypermethylation in drug resistance to 5‐fluorouracil in colorectal cancer cell lines

  2003cited by this paper
• DNA mismatch repair and cancer.

  2003cited by this paper
• Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.

  2003cited by this paper
• Characterization of sporadic colon cancer by patterns of genomic instability.

  2003cited by this paper
• Cellular effects of CPT‐11 on colon carcinoma cells: Dependence on p53 and hMLH1 status

  2002cited by this paper
• Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses.

  2001cited by this paper
• Instabilotyping: comprehensive identification of frameshift mutations caused by coding region microsatellite instability.

  2001cited by this paper
• Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level.

  2001influential reference
• Tumor‐infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma

  2001cited by this paper
• Resistance to topoisomerase poisons due to loss of DNA mismatch repair

  2001cited by this paper
• Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis.

  2001influential reference
• Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer.

  2000cited by this paper
• Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy.

  2000cited by this paper
• Genetic reconstruction of individual colorectal tumor histories.

  2000cited by this paper
• p53 Gene Mutation, Microsatellite Instability and Adjuvant Chemotherapy: Impact on Survival of 388 Patients with Dukes’ C Colon Carcinoma

  2000cited by this paper
• Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer.

  2000influential reference
• Colorectal cancer prevention and treatment.

  2000cited by this paper
• Mutations of transforming growth factor beta 1 type II receptor, BAX, and insulin-like growth factor II receptor genes in microsatellite unstable cell lines.

  2000cited by this paper
• A role for ATR in the DNA damage-induced phosphorylation of p53.

  1999cited by this paper
• Germ-line msh6 mutations in colorectal cancer families.

  1999cited by this paper
• The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage

  1999cited by this paper
• Mismatch repair proficiency and in vitro response to 5-fluorouracil.

  1999cited by this paper
• Familial endometrial cancer in female carriers of MSH6 germline mutations

  1999cited by this paper
• hMutSalpha- and hMutLalpha-dependent phosphorylation of p53 in response to DNA methylator damage.

  1999cited by this paper
• Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas.

  1998cited by this paper
• Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers.

  1998cited by this paper
• A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.

  1998cited by this paper
• Isolation of MutSbeta from human cells and comparison of the mismatch repair specificities of MutSbeta and MutSalpha.

  1998cited by this paper
• Prognostic significance of DNA replication errors in young patients with colorectal cancer.

  1998cited by this paper
• Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.

  1998cited by this paper
• Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma.

  1998cited by this paper
• Somatic Frameshift Mutations in the BAX Gene in Colon Cancers of the Microsatellite Mutator Phenotype

  1997cited by this paper
• Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin.

  1997cited by this paper
• Germ-line mutation of the hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred.

  1997cited by this paper
• Mismatch repair in replication fidelity, genetic recombination, and cancer biology.

  1996cited by this paper
• The role of DNA mismatch repair in platinum drug resistance.

  1996cited by this paper
• Loss of DNA mismatch repair in acquired resistance to cisplatin.

  1996cited by this paper
• hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6.

  1996cited by this paper
• Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N'-nitro-N-nitrosoguanidine.

  1996cited by this paper
• Frameshift mutator mutations

  1996cited by this paper
• DNA mismatch binding defects, DNA damage tolerance, and mutator phenotypes in human colorectal carcinoma cell lines.

  1995cited by this paper
• Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint.

  1995cited by this paper
• Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability.

  1995cited by this paper
• Fluorouracil plus Levamisole as Effective Adjuvant Therapy after Resection of Stage III Colon Carcinoma: A Final Report

  1995cited by this paper
• Genomic instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation

  1994cited by this paper
• Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation.

  1994cited by this paper
• Genetic steps in colorectal cancer

  1994cited by this paper
• Mutation in the DNA mismatch repair gene homologue hMLH 1 is associated with hereditary non-polyposis colon cancer

  1994cited by this paper
• Mutation of a mutL homolog in hereditary colon cancer.

  1994cited by this paper
• Microsatellite instability in cancer of the proximal colon.

  1993cited by this paper
• Clues to the pathogenesis of familial colorectal cancer.

  1993cited by this paper
• Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer.

  1993cited by this paper
• Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis

  1993cited by this paper
• The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer.

  1993cited by this paper
• Heteroduplex repair in extracts of human HeLa cells.

  1991cited by this paper
• Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.

  1990cited by this paper
• A genetic model for colorectal tumorigenesis.

  1990cited by this paper
• Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.

  1990cited by this paper
• Metabolism and mechanism of action of 5-fluorouracil.

  1990cited by this paper
• Cancer statistics

  1989cited by this paper
• Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic.

  1989cited by this paper
• Dissociation of 5-fluorouracil-induced DNA fragmentation from either its incorporation into DNA or its cytotoxicity in murine T-lymphoma (S-49) cells.

  1987cited by this paper
• DNA lesions in human neoplastic cells and cytotoxicity of 5-fluoropyrimidines.

  1986cited by this paper
• Lymphocytic infiltration and survival in rectal cancer.

  1986cited by this paper
• One role for DNA methylation in vertebrate cells is strand discrimination in mismatch repair.

  1985cited by this paper
• 5-Fluorouracil incorporation in DNA of human breast carcinoma cells.

  1982cited by this paper
• Fluorinated pyrimidines as tight-binding inhibitors of thymidylate synthetase.

  1981cited by this paper
• The role of deoxyuridine triphosphate nucleotidohydrolase, uracil-DNA glycosylase, and DNA polymerase alpha in the metabolism of FUdR in human tumor cells.

  1980cited by this paper
• Mechanism for exclusion of 5-fluorouracil from DNA.

  1980cited by this paper

• Mutation and Microsatellite Instability (MSI) Affect the Differential Gene Expression of Folic Acid and 5-Flourouracil Metabolism-Related Genes in Colorectal Carcinoma

  2025cites this paper
• Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors

  2024cites this paper
• Unanticipated pathological clearance in two cases of clinical T4b dMMR/MSI-h advanced colorectal cancer: the potential of immune checkpoint inhibitors despite positive positron-emission tomography results

  2024cites this paper
• Genomic instabilities in hepatocellular carcinoma: biomarkers and application in immunotherapies.

  2024cites this paper
• Personalized treatment using predictive biomarkers in solid organ malignancies: A review

  2024cites this paper
• Microsatellite Instability with BRAF V600E Associated with Delayed Presentation but Poor Survival in Stage III Colorectal Cancer

  2023cites this paper
• Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors

  2023cites this paper
• The Anti-Tumor Effect of the Newly Developed LAT1 Inhibitor JPH203 in Colorectal Carcinoma, According to a Comprehensive Analysis

  2023cites this paper
• Long-term resistance to 5-fluorouracil promotes epithelial-mesenchymal transition, apoptosis evasion, autophagy, and reduced proliferation rate in colon cancer cells.

  2022cites this paper
• IL-1β enhances cell viability and decreases 5-FU sensitivity in novel colon cancer cell lines derived from African American patients

  2022cites this paper
• Global trend of colorectal cancer, prevention, and control in China: Challenges and strategies

  2022cites this paper
• Consequences of the Hsp110DE9 mutation in tumorigenesis and the 5-fluorouracil-based chemotherapy response in Msh2-deficient mice

  2022cites this paper
• Assimilating Epigenetics and Transcriptomics for the Identification of Prognostic Novel Biomarkers and Imminent Targets in Colorectal Carcinoma with Therapeutic Potential.

  2022cites this paper
• Neoadjuvant chemotherapy in patients undergoing colonic resection for locally advanced nonmetastatic colon cancer: A nationwide propensity score matched cohort study

  2022cites this paper
• Curcumin and NCLX inhibitors share anti-tumoral mechanisms in microsatellite-instability-driven colorectal cancer

  2022cites this paper
• Challenges of Neoantigen Targeting in Lynch Syndrome and Constitutional Mismatch Repair Deficiency Syndrome

  2021cites this paper
• Predictive and prognostic biomarkers with therapeutic targets in colorectal cancer: A 2021 update on current development, evidence, and recommendation

  2021cites this paper
• Global colorectal cancer burden in 2020 and projections to 2040

  2021cites this paper
• Predictive biomarkers for 5-fluorouracil and oxaliplatin-based chemotherapy in gastric cancers via profiling of patient-derived xenografts

  2021cites this paper
• Relationship between microsatellite status and immune microenvironment of colorectal cancer and its application to diagnosis and treatment

  2021cites this paper
• Can hypoxia-inducible factor-1α overexpression discriminate human colorectal cancers with different microsatellite instability?

  2021cites this paper
• Mapping the genomic diaspora of gastric cancer

  2021cites this paper
• Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy.

  2021cites this paper
• Radiogenomics in Colorectal Cancer

  2021cites this paper
• Predicting the effect of 5‐fluorouracil–based adjuvant chemotherapy on colorectal cancer recurrence: A model using gene expression profiles

  2020cites this paper
• Neoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series.

  2020cites this paper
• Treating Colorectal Cancer with Immunotherapy: Implications for Single Versus Combination Therapy

  2020cites this paper
• Personalized Medicine—Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer

  2020cites this paper
• Immunohistochemical pattern– a prognostic factor for synchronous gastrointestinal cancer

  2020cites this paper
• Neoadjuvant Immunotherapy in Microsatellite-Instability High Nonmetastatic Colorectal Cancer: A Single-institute Experience and Review of the Literature.

  2020cites this paper
• Implications of Hereditary Origin on the Immune Phenotype of Mismatch Repair-Deficient Cancers: Systematic Literature Review

  2020cites this paper
• Clinicopathological importance of colorectal medullary carcinoma

  2019cites this paper
• 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future.

  2019cites this paper
• Molecular Diagnostics in Colorectal Cancer

  2019cites this paper
• Passenger mutations accurately classify human tumors

  2019cites this paper
• Biomarker-guided therapy for colorectal cancer: strength in complexity

  2019cites this paper
• Evaluation of Acid Ceramidase as Response Predictor and Therapeutic Target in Neoadjuvant Chemoradiotherapy for Rectal Cancer

  2019cites this paper
• Impact of Time to Start Systemic Therapy on the Outcomes of Patients with Metastatic Colorectal Cancer Treated with First Line FOLFOX Chemotherapy; a Patient-Level Pooled Analysis of Two Clinical Trials

  2018cites this paper
• Impact of primary tumor side on the outcomes of patients with non-metastatic colon cancer; a patient-level pooled analysis of two clinical trials

  2018cites this paper
• COLORECTAL CARCINOMAS IN NATIONAL HOSPITAL ABUJA, NIGERIA

  2018cites this paper
• Possible role of nuclear β‐catenin in resistance to preoperative chemoradiotherapy in locally advanced rectal cancer

  2017cites this paper
• Análisis del riesgo de cáncer colorrectal en pacientes con múltiples pólipos serrados y estudio de marcadores moleculares con implicaciones en su diagnóstico y prevención

  2017cites this paper
• Stratification of Digestive Cancers with Different Pathological Features and Survival Outcomes by MicroRNA Expression

  2016cites this paper
• Low-fidelity alternative DNA repair carcinogenesis theory may interpret many cancer features and anticancer strategies.

  2016cites this paper
• Biomarker-directed Targeted Therapy in Colorectal Cancer.

  2015cites this paper
• Colorectal Cancer Biomarkers: Where Are We Now?

  2015cites this paper
• The Molecular Pathogenesis of Colorectal Cancer and Its Potential Application to Colorectal Cancer Screening

  2015cites this paper
• Efficacy of Adjuvant 5-Fluorouracil Therapy for Patients with EMAST-Positive Stage II/III Colorectal Cancer

  2015cites this paper
• Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer.

  2015cites this paper
• Molecular biology of colorectal cancer in clinical practice

  2015cites this paper
• Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer.

  2015cites this paper
• Environmental Exposures, Tumor Heterogeneity, and Colorectal Cancer Outcomes

  2014cites this paper
• DNA testing and molecular screening for colon cancer.

  2014cites this paper
• Molecular Alterations and Biomarkers in Colorectal Cancer

  2014influential citation
• Značaj određivanja mikrosatelitne nestabilnosti kao genetskog markera u kolorektalnom karcinomu

  2013cites this paper
• Molecular tumor testing for Lynch syndrome in patients with colorectal cancer.

  2013cites this paper
• Dysregulation and crosstalk of cellular signaling pathways in colon carcinogenesis.

  2013cites this paper
• Transcatheter hepatic therapy with irinotecan eluting beads (DEBIRI) for the treatment of colorectal liver metastases

  2013cites this paper
• Assessing colorectal cancer heterogeneity: one step closer to tailored medicine

  2013cites this paper
• PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer with poor prognosis

  2012influential citation
• ADVANCES IN TRANSLATIONAL SCIENCE

  2012cites this paper
• hMLH1 promoter hypermethylation and MSI status in human endometrial carcinomas with and without metastases

  2012cites this paper
• Predictive and Prognostic Factors in Colorectal Cancer: A Personalized Approach

  2011cites this paper
• Clinical significance of microsatellite instability for stage II or III colorectal cancer following adjuvant therapy with doxifluridine

  2011cites this paper
• Perspectives for tailored chemoprevention and treatment of colorectal cancer in Lynch syndrome.

  2011cites this paper
• PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis

  2011cites this paper
• High Tumour Cannabinoid CB1 Receptor Immunoreactivity Negatively Impacts Disease-Specific Survival in Stage II Microsatellite Stable Colorectal Cancer

  2011cites this paper
• Inherited and Somatic Genetic factors in Colorectal Cancer Development

  2011cites this paper
• Association between deficient mismatch repair system and efficacy to irinotecan‐containing chemotherapy in metastatic colon cancer

  2011cites this paper
• Molekularne modele nowotworzenia w raku jelita i odbytnicy

  2010cites this paper
• Secondary Prevention of Colorectal Cancer: Is There an Optimal Follow-up for Patients with Colorectal Cancer?

  2010cites this paper
• Colorectal cancer molecular biology moves into clinical practice

  2010cites this paper
• Improved Testing for Microsatellite Instability in Colorectal Cancer Using a Simplified 3-Marker Assay

  2010cites this paper
• Thymidylate synthase expression and mismatch repair protein expression in colorectal cancer

  2010cites this paper
• Genetic Epidemiology of Mismatch Repair Deficiency in Ovarian Cancer

  2010cites this paper
• Germline determinants of outcome and risk in colorectal cancer

  2010cites this paper
• Telomerase Inhibition Potentiates the Effects of Genotoxic Agents in Breast and Colorectal Cancer Cells in a Cell Cycle – Specific Manner

  2010cites this paper
• Telomerase inhibition potentiates the effects of genotoxic agents in breast and colorectal cancer cells in a cell cycle-specific manner.

  2010cites this paper
• Differential expression of hMLH1 in sporadic human colorectal cancer tumors and distant metastases

  2009cites this paper
• Evolving molecular classification by genomic and proteomic biomarkers in colorectal cancer: potential implications for the surgical oncologist.

  2009cites this paper
• Value of the identification of microsatellite instability in colorectal cancer

  2009cites this paper
• Genetic prognostic and predictive markers in colorectal cancer

  2009cites this paper
• Molecular pathology of colorectal cancer predisposing syndromes

  2008cites this paper
• X-linked inhibitor of apoptosis (XIAP) in colorectal cancer models

  2008cites this paper
• Concordance Between Tumor and Germline DNA

  2008cites this paper
• Molecular Testing for Microsatellite Instability and DNA Mismatch Repair Defects in Hereditary and Sporadic Colorectal Cancers – Ready for Prime Time?

  2007cites this paper
• Molecular profiling and risk stratification of adenocarcinoma of the colon

  2007cites this paper